URGN Latest Press Releases

-- November 4, 2026 --

UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights Globe Newswire 8:00 AM

-- November 3, 2026 --

UroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference Globe Newswire 8:00 AM

-- November 2, 2026 --

UroGen Announces First Patient Dosed in Phase 1 Trial of UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer Globe Newswire 8:00 AM

-- October 28, 2026 --

UroGen's Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial Cancer Globe Newswire 8:00 AM

-- October 27, 2026 --

UroGen Pharma to Report Third Quarter 2026 Financial Results on Wednesday, November 4th, 2026 Globe Newswire 6:00 PM

-- October 19, 2026 --

UroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBC Globe Newswire 8:00 AM

-- September 4, 2026 --

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 8:00 AM

-- September 2, 2026 --

UroGen Pharma to Present at Upcoming Investor Conferences Globe Newswire 8:00 AM

-- August 20, 2026 --

IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies PRNewswire 7:05 AM

UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline Globe Newswire 7:00 AM

-- August 17, 2026 --

UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC Globe Newswire 8:00 AM

-- August 5, 2026 --

UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights Globe Newswire 8:00 AM

-- July 29, 2026 --

UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026 Globe Newswire 8:00 AM

-- July 15, 2026 --

UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI and UGN-103 Globe Newswire 8:00 AM

-- July 8, 2026 --

UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer Globe Newswire 8:00 AM

Market Data Delayed 15 Minutes